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Longitudinal epigenome-wide association
studies of three male military cohorts
reveal multiple CpG sites associated with
post-traumatic stress disorder
Clara Snijders1†, Adam X. Maihofer2,3,4†, Andrew Ratanatharathorn5, Dewleen G. Baker2,3,6, Marco P. Boks7,
Elbert Geuze7,8, Sonia Jain9, Ronald C. Kessler10, Ehsan Pishva1,11, Victoria B. Risbrough2,3,4, Murray B. Stein2,6,12,
Robert J. Ursano13, Eric Vermetten14,15,16,17, Christiaan H. Vinkers18,19, PGC PTSD EWAS Consortium,
Alicia K. Smith20,21, Monica Uddin22, Bart P. F. Rutten1† and Caroline M. Nievergelt1,2,3,4*†
Abstract
Background: Epigenetic mechanisms have been suggested to play a role in the development of post-traumatic
stress disorder (PTSD). Here, blood-derived DNA methylation data (HumanMethylation450 BeadChip) collected prior
to and following combat exposure in three cohorts of male military members were analyzed to assess whether
DNA methylation profiles are associated with the development of PTSD. A total of 123 PTSD cases and 143 trauma-
exposed controls were included in the analyses. The Psychiatric Genomics Consortium (PGC) PTSD EWAS QC
pipeline was used on all cohorts, and results were combined using a sample size weighted meta-analysis in a two-
stage design. In stage one, we jointly analyzed data of two new cohorts (N = 126 and 78) for gene discovery, and
sought to replicate significant findings in a third, previously published cohort (N = 62) to assess the robustness of
our results. In stage 2, we aimed at maximizing power for gene discovery by combining all three cohorts in a meta-
analysis.
Results: Stage 1 analyses identified four CpG sites in which, conditional on pre-deployment DNA methylation, post-
deployment DNA methylation was significantly associated with PTSD status after epigenome-wide adjustment for
multiple comparisons. The most significant (intergenic) CpG cg05656210 (p = 1.0 × 10−08) was located on 5q31 and
significantly replicated in the third cohort. In addition, 19 differentially methylated regions (DMRs) were identified,
but failed replication. Stage 2 analyses identified three epigenome-wide significant CpGs, the intergenic CpG
cg05656210 and two additional CpGs located in MAD1L1 (cg12169700) and HEXDC (cg20756026). Interestingly,
cg12169700 had an underlying single nucleotide polymorphism (SNP) which was located within the same LD block
as a recently identified PTSD-associated SNP in MAD1L1. Stage 2 analyses further identified 12 significant differential
methylated regions (DMRs), 1 of which was located in MAD1L1 and 4 were situated in the human leukocyte
antigen (HLA) region.
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Conclusions: This study suggests that the development of combat-related PTSD is associated with distinct
methylation patterns in several genomic positions and regions. Our most prominent findings suggest the
involvement of the immune system through the HLA region and HEXDC, and MAD1L1 which was previously
associated with PTSD.
Keywords: EWAS, Longitudinal, DNA methylation, Meta-analysis, Trauma, PTSD, Epigenetics
Background
Post-traumatic stress disorder (PTSD) is a debilitating
psychiatric disorder that can develop following direct or
indirect exposure to a potentially life-threatening trau-
matic incident. Symptoms include persistent re-
experiencing of the trauma, avoidance behavior, hyper-
arousal, and negative mood [1]. Although most individ-
uals have the potential to withstand negative effects of
trauma exposure on long-term mental health and to re-
cover promptly, some are more vulnerable and at in-
creased risk of developing PTSD. Understanding the
molecular and neurobiological underpinnings of this dif-
ferential susceptibility is currently receiving considerable
attention, and epigenetic mediation of environmental in-
fluences has been proposed as a potential key mechan-
ism [2–4].
Several epigenome-wide association studies (EWAS)
have aimed to identify differentially methylated CpGs in
PTSD [5–8]. However, most of these studies are based
on association analyses where methylation was assessed
at a single time point (cross-sectional), with limited abil-
ity to adjust for confounding variables. Only one PTSD
study to date reported longitudinal changes in methyla-
tion profiles across a period of combat exposure in order
to capture changes in DNA methylation over time in re-
lation to phenotypic changes [7]. We made use of the
Prospective Research In Stress-related Military Opera-
tions (PRISMO) study, which in the present study was
used as a replication cohort.
Here, we followed a previously published two-stage de-
sign [9] where we first meta-analyzed two longitudinal,
USA-based military cohorts in order to identify associa-
tions between changes in methylation levels from pre-
deployment to post-deployment and the development of
PTSD. We then sought replication of our significant
findings in PRISMO. In the second stage, we combined
all three cohorts in a meta-analysis. This two-stage ap-
proach allows us to investigate the robustness of our
findings through replication in stage 1, while increasing
power for gene discovery by combining all three studies
in stage 2. For all three cohorts, DNA methylation data
and phenotypic data were collected prior to and follow-
ing a 4–7-month deployment to an active ware zone in
Iraq or Afghanistan. All studies selected PTSD cases and
controls at post-deployment and only included subjects
without PTSD at pre-deployment. Of the significant
CpGs in the second analysis stage, we assessed associa-
tions with nearby single nucleotide polymorphisms
(SNPs) and gene expression data, and examined correla-
tions between blood and brain methylation status. To
the best of our knowledge, this is the largest study aimed
at detecting methylation changes associated with the de-
velopment of PTSD. This prospective and longitudinal
analysis permits us to more accurately capture dynamic
changes in DNA methylation in relation to PTSD devel-
opment while minimizing confounding due to intra-
individual variability.
Results
Cohorts
Three military cohorts were included in this study, i.e.,
the US Marine Resiliency Study (MRS), the US Army
Study to Assess Risk and Resilience in Servicemembers
(Army STARRS), and the Dutch PRISMO study. Demo-
graphic and clinical characteristics of subjects from all
three cohorts (total N subjects = 266) can be found in
Table 1. All subjects were male, and the majority were
of European ancestry (N = 211, 79%). Within each co-
hort, cases and controls did not differ significantly in
terms of age. Pre-deployment PTSD symptoms were sig-
nificantly different between cases and controls from
MRS only, with cases scoring slightly higher on the Clin-
ician Administered PTSD Scale (CAPS) as compared to
controls (p = .002; Table 1). In MRS and Army STARRS,
cases were exposed to more traumatic events as com-
pared to controls (p < .001 for both cohorts).
Stage 1: meta-analysis of MRS and Army STARRS
Data from MRS and Army STARRS were combined in
order to identify CpG sites in which, conditional on
baseline DNA methylation, post-deployment methyla-
tion was associated with PTSD status. Four genome-
wide significant CpG sites (i.e., differentially methylated
positions, DMPs) were identified using a conservative
Bonferroni threshold of p = 1.13 × 10−07 for the 450K
EWAS array (Table 2). These sites were located near
SPRY4, in SDK1, CTRC, and CDH15. The direction of
DNA methylation profiles associated with PTSD devel-
opment was different for each site (Additional file 1: Fig-
ures S1-4). Additionally, after the Bonferroni correction
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for ~ 26,000 predefined regions, 19 differentially methyl-
ated regions (DMRs) were identified in which, condi-
tional on baseline DNA methylation, post-deployment
methylation was significantly associated with PTSD sta-
tus (Table 3).
Replication in PRISMO
After the Bonferroni correction for the four significant
DMPs and when using a one-sided test, the association
of one CpG site, the intergenic site cg05656210, was rep-
licated in PRISMO (p = 2.0 × 10−02; Table 2). Both the
discovery meta-analysis and replication analysis show
decreased DNA methylation in association with PTSD
status. None of the 19 significant DMRs were replicated
in PRISMO (Table 3).
Stage 2: meta-analysis of MRS, Army STARRS, and
PRISMO
When combining MRS, Army STARRS, and PRISMO,
the DNA methylation profile of three CpG sites was sig-
nificantly associated with post-deployment PTSD status
(Table 2, Fig. 1). The intergenic CpG that replicated in
PRISMO remained the most significant (Z = − 6.14, p =
8.1 × 10−10). The other sites were located in the gene
body regions of MAD1L1 and HEXDC (Additional file 1:
Figures S1, S5, S6). Sensitivity analyses for the potentially
confounding effects of changes in smoking and alcohol
use did not substantially affect these results (Additional
file 1: Table S1). Furthermore, 12 DMRs were identified
(Additional file 1: Figures S7-18, Fig. 1), 7 of which were
also significant in stage 1 and 4 were located in the hu-
man leukocyte antigen (HLA) region (Table 3).
Genetic effects and gene expression
Using MRS data, genetic effects on DNA methylation
levels of the significant DMPs were assessed by testing
for associations with SNPs within 500 kb of the DMPs.
All DMPs had significantly associated SNPs which ex-
plained approximately 80% of the variation in methyla-
tion (p < 2 × 10−16) and were located within 1 bp of
their respective CpG sites (Additional file 1: Table S2).
However, adjusting for genotypes in the main model to
assess the impact of SNPs on the association between
DNA methylation and PTSD did not substantially affect
the observed findings (Additional file 1: Table S3). We
further assessed the association between baseline or
post-deployment methylation signatures of these DMPs
and corresponding blood-derived gene expression data
which was available for MRS [10]. At baseline, methyla-
tion levels of the CpGs located in HEXDC and MAD1L1
were significantly correlated with gene expression data
(Table 4), with an inverse correlation between DNA
methylation and expression in HEXDC and a positive
correlation between methylation and expression of
MAD1L1. Post-deployment DNA methylation values
correlated to gene expression of HEXDC only. Methyla-
tion of the intergenic site cg05656210 was not signifi-
cantly associated with expression of the closest gene at
any time point. We additionally assessed the association
between changes in expression and changes in methyla-
tion for these DMPs and found no significant associa-
tions (Table 4).
Blood-brain correlations of PTSD-associated CpGs
Blood-brain correlations of methylation levels of the sig-
nificant stage 2 DMPs were examined using a publicly
Table 1 Demographics and clinical characteristics of MRS, Army
STARRS, and PRISMO
Cases Controls p value Overall
Number
MRS 63 63 – 126
Army STARRS 31 47 – 78
PRISMO 29 33 – 62
Age, mean (SD)
MRS 22.15 (2.3) 22.36 (3.7) .71 22.26 (3)
Army STARRS 23.5 (4.0) 24.6 (4.8) .26 24.2 (4.4)
PRISMO 27.1 (9.9) 27.1 (8.7) 1.0 27.1 (9.0)
PTSD pre-deployment, mean (SD)
MRS, CAPS 10.8 (7.5) 6.8 (6.5) .002 8.8 (7)
Army STARRS, PCL-6 7.4 (2.6) 6.8 (2.0) .40 7.0 (2.2)
PRISMO, SRIP 28.2 (4.0) 26.4 (4.0) .10 27.2 (3.9)
PTSD post-deployment, mean (SD)
MRS, CAPS 58.17 (13.5) 13.36 (6.1) < .001 35.76 (9.8)
Army STARRS, PDL-C 52.7 (7.8) 25.8 (8.6) < .001 36.5 (8.1)
PRISMO, SRIP 46.1 (8.7) 27.4 (5.1) < .001 36.1 (6.5)
Combat exposure, mean (SD)
MRS, DDRI 1.08 (0.8) 0.66 (0.4) < .001 0.87 (0.6)
Army STARRS, PCL 9.4 (1.3) 7.9 (2.0) < .001 8.5 (1.7)
PRISMO, DEC 8.5 (3.0) 7.2 (2.3) .07 7.8 (2.5)
Ancestry, N (%)
MRS
European 34 (53) 37 (59) – 71 (56)
African 5 (8) 5 (8) – 10 (8)
Other 24 (39) 21 (33) – 45 (36)
Army STARRS
European 31 (100) 47 (100) – 78 (100)
PRISMO
European 29 (100) 33 (100) – 62 (100)
CAPS Clinician-Administered PTSD Scale, PCL-6 PTSD Checklist—screener, SRIP
Self-Report Inventory for PTSD, PCL-C PTSD Checklist—civilian version, DDRI
Deployment Risk and Resilience Inventory, DEC deployment experiences
checklist, SD standard deviation. Each study used different scales for PTSD and
combat exposure scores; the corresponding scales are included in the
row names
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available database [11]. For all three DMPs, blood DNA
methylation levels correlated strongly with those in the
prefrontal cortex, entorhinal cortex, superior temporal
gyrus, and cerebellum (r ≥ 0.93 for all sites; p values ran-
ging between 1.48 × 10−32 and 5.32 × 10−72; Additional
file 1: Table S4, Additional file 1: Figure S19 for
cg05656210).
Discussion
Exposure to trauma is a prerequisite for the develop-
ment of PTSD, yet not all individuals develop PTSD fol-
lowing trauma [12]. The underlying biological
mechanisms of this differential susceptibility have not
yet been fully identified, and even the largest genome-
wide association studies (GWAS) to date explain only a
small proportion of the disease liability [13, 14]. Epigen-
etic changes have been studied as one potential mechan-
ism, but most association studies have used cross-
sectional designs which render it impossible to establish
causality. Here, we use a more powerful longitudinal de-
sign to investigate associations of DNA methylation with
post-deployment PTSD status across very similar mili-
tary cohorts deployed to combat in Iraq and
Afghanistan. We started with combining the USA-based
MRS and Army STARRS cohorts and sought replication
using the previously published Dutch PRISMO study [7].
To maximize power for new discoveries, we also per-
formed a meta-analysis across all three cohorts. The first
Fig. 1 Manhattan plot showing the results of the stage 2 meta-analysis across 3 epigenome-wide association studies (MRS, Army STARRS,
PRISMO). The upper part shows the 3 significant differentially methylated positions (DMPs) while the lower part shows the 12 significant
differentially methylated regions (DMRs). Red lines indicate significance thresholds after the Bonferroni corrections for ~ 485,000 (top) and 26,000
(bottom) comparisons, respectively
Table 4 Correlations between methylation levels of DMPs and gene expression data from MRS
CpG Gene Baseline corr (r) p value Post-deployment corr (r) p value Change corr (r) p value
cg20756026 HEXDC − 0.28 2.00E−03 − 0.24 8E−03 − 0.01 0.88
cg12169700 MAD1L1 0.23 1.00E−02 0.06 0.49 − 0.07 0.46
cg05656210 SPRY4* 0.08 3.80E−01 0.11 0.21 0.10 0.27
Significance is indicated in italics. Corr correlation
*Closest gene
Snijders et al. Clinical Epigenetics           (2020) 12:11 Page 6 of 13
analysis stage revealed 4 genome-wide significant DMPs
and 19 DMRs which were linked to post-deployment
PTSD status. One of these DMPs replicated in PRISMO.
In the second stage, a meta-analysis of all 3 studies re-
vealed that the replicating DMP and 7 DMRs remained
significant, and 2 additional DMPs and 12 DMRs were
identified.
The replicating DMP cg05656210 remained the top-
ranked significant marker in the second analysis stage.
This CpG site is an intergenic site annotated near
SPRY4. SPRY4 is a member of the Sprouty proteins
which are mainly involved in inhibiting receptor tyrosine
kinase (RTK) signaling [15]. Upon activation by growth
factor ligands, RTK signaling has a wide variety of down-
stream effects ranging from the regulation of cell prolif-
eration and differentiation to the modulation of cellular
metabolism [16]. One particular receptor involved in
RTK signaling, i.e., receptor tyrosine kinase B (TrkB),
and its main ligand, brain-derived neurotrophic factor
(BDNF), have repeatedly been shown to be affected in
stress-related disorders such as depression [17]. Consist-
ently, two independent studies reported decreased
mRNA levels of BDNF and TrkB in the prefrontal cortex
and hippocampus of individuals who committed suicide
as compared to healthy control subjects [18, 19]. More-
over, SPRY4-IT1, a long non-coding RNA derived from
the second intron of SPRY4 [20], has been shown to
interact with SKA2 [21], a gene that was suggested to be
a promising biomarker for suicidal behavior [22, 23],
stress susceptibility, and stress-related disorders such as
PTSD [23–25]. Finally, SPRY4 was previously found dif-
ferentially methylated in the blood of patients diagnosed
with schizophrenia [26]. Together, these results suggest
that alterations within SPRY4 could contribute to psychi-
atric disorders such as depression, PTSD, and schizo-
phrenia and potentially play a role in suicidal behavior.
The question as to whether and how the identified DMP
influences the expression of SPRY4 and is involved in
these phenotypes still remains to be answered.
The second top significant probe, cg12169700, and
one DMR are located within MAD1L1. MAD1L1 is part
of the mitotic spindle-assembly checkpoint (SAC) which
monitors the proper attachment of chromosomes to the
microtubule spindle apparatus, delays the start of ana-
phase until all chromosomes are properly attached, and
in doing so, ensures correct chromosome separation [27,
28]. Malfunctions of the MAD1L1 protein could there-
fore contribute to aneuploidy and chromosomal instabil-
ity. Specific SNPs within this gene have previously been
associated with bipolar disorder [29, 30], schizophrenia
[30–32], and depression [33]. Interestingly, MAD1L1
was recently identified in a PTSD GWAS of the Million
Veteran Program (MVP) [34]. The SNP that underlies
cg12169700, rs11761270, is located in the same large
linkage disequilibrium (LD) block as the MVP finding.
In the MVP, carriers of the minor allele of rs11761270
showed decreased levels of methylation and were at in-
creased risk of having PTSD. This corresponds to our
own findings in which PTSD cases show a reduction in
methylation from pre- to post-deployment. Moreover,
using expression data from MRS, we found that methy-
lation at this site was positively associated with gene ex-
pression of MAD1L1. This also aligns with previous
findings that showed that blood levels of MAD1L1 were
decreased in highly stress-susceptible individuals [35].
Together, these findings suggest that specific methyla-
tion profiles within MAD1L1 may be regarded as a risk
factor for PTSD in addition to several other psychiatric
disorders [36]. However, the underlying mechanisms
through which such disturbances could contribute to
psychiatric disorders warrant further research.
The third CpG site is located in HEXDC which to date
has no known implications in any psychiatric disease.
Although the biological functions of its product, hexosa-
minidase D, remain largely unknown, it is believed to be
a glycosidase and previous studies found associations
with rheumatoid arthritis [37, 38]. Interestingly, recent
studies found significant pleiotropy between rheumatoid
arthritis and PTSD [39], and rheumatoid arthritis and
schizophrenia [40]. Other studies found associations be-
tween PTSD symptoms and rheumatoid arthritis in a
twin population [41] and in an epidemiological study of
military veterans [42]. This link between mental disor-
ders and immune-related processes is discussed more in
detail below. The DMP of HEXDC was located directly
adjacent to rs4789774, a known expression quantitative
trait locus (eQTL) that regulates the expression of
HEXDC in the human brain cortex and of NARF and
NARF-IT1 in a number of tissue types including blood
(http://genome.ucsc.edu/). Moreover, a modest negative
correlation was found between methylation of this site
and gene expression of HEXDC, both at baseline and at
post-deployment.
Twelve significant DMRs were found in the second
phase of the analysis. Our strongest finding was in the
HLA region, a gene-dense region which contains over
200 genes that encode human leukocyte antigen com-
plex proteins in charge of presenting peptide antigens to
trigger immune reactions, among other (non-)immune
functions [43]. Their non-immunological roles include
processes such as neurodevelopment, synaptic plasticity,
learning, memory, and stress reactivity [44, 45]. It is
therefore not entirely surprising that several epigenetic
modifications and genetic variants within this region
have repeatedly been found implicated in neuropsychi-
atric disorders such as schizophrenia and bipolar dis-
order (recently reviewed in [46]). Along with our
HEXDC finding, these observations further enhance the
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existing notion that immune factors play an important
role and should continue to be studied in relation to
mental disorders such as PTSD [47]. Although it is now
clear that immune imbalances are present in PTSD,
questions related to causality and further implications
for prevention strategies and treatment options largely
remain to be answered.
Follow-up analyses were done using the significant
DMPs from the stage 2 meta-analysis only. The discov-
ery that methylation levels at the top three PTSD-
associated CpGs were highly associated with the geno-
type of the nearby SNPs led us to question whether the
associations between methylation and PTSD status were
mainly driven by genotype. However, direct adjustment
for genotype in a sensitivity analysis did not attenuate
the associations between DNA methylation and PTSD
status and our current sample size limits our ability to
conduct analyses specific to genotype strata to further
investigate interaction effects between SNPs and
methylation.
Since our methylation data were based on DNA from
peripheral blood, we further examined correlations be-
tween blood and several brain regions, i.e., the prefrontal
cortex, entorhinal cortex, superior temporal gyrus, and
cerebellum. The results indicate that blood-brain corre-
lations of all top DMPs were strong for all four brain re-
gions suggesting that these findings could potentially
also be relevant for tissues other than blood. Assessing
these correlations is relevant when dealing with disor-
ders such as PTSD which are characterized by functional
and structural alterations within the brain but for which
the accessibility to human brain tissue is limited. How-
ever, these and similar findings will need to be con-
firmed using postmortem brain tissue and their precise
role in PTSD development will need to be investigated
further.
The main limitation of the present study is its small
sample size which likely captures only a fraction of all
implicated CpGs and renders additional analyses such as
pathway and network analyses underpowered. It further
needs to be emphasized that this study used data gener-
ated with Illumina’s 450K arrays which only assess a
subset of all CpG sites. Next, although examining blood-
derived DNA methylation is informative when seeking
relatively easily accessible biomarkers, follow-up studies
are needed in order to assess these methylation patterns
within the tissue of interest, i.e., the brain. Another im-
portant limitation of the study is the fact that subjects
that developed PTSD were exposed to significantly more
traumatic events than control subjects in MRS and
Army STARRS. One way to address these differences
would be to include trauma exposure as a covariate.
However, given the high correlation between trauma ex-
posure and PTSD, this would likely diminish the
association of methylation changes and PTSD. There-
fore, we acknowledge that our analyses may include as-
sociations with trauma exposure in addition to PTSD.
Next, the limited replication of findings from the US co-
horts in the Dutch PRISMO study, and vice versa [7],
may point to type I errors, or be partially due to small
sample sizes and/or heterogeneity in study designs, study
environments, and potential confounders such as im-
mune status or medication use. For example, findings re-
ported from PRISMO [7] point towards the involvement
of DMPs and DMRs located within ZFP57, RNF39, and
HIST1H2APS2, which were not implicated in our ana-
lyses. However, these genes are located within the HLA
region, a region which is indeed implicated in our ana-
lyses. Furthermore, whereas the PRISMO study is en-
tirely based on subjects of European ancestry, the US
MRS and Army STARRS studies include more ancestral
diversity. Genes in the HLA region tend to be highly
polymorphic, particularly with respect to ancestral back-
ground [48]. Thus, it is possible that this heterogeneity
may contribute to the lack of replication. Further ana-
lyses should be ancestry-specific, once sample sizes are
adequate. Furthermore, at this stage, it is unclear
whether the identified differential methylation patterns
in PTSD cases have any functional consequences. Al-
though they may influence gene expression, the current
dataset has limited power to establish causality. In order
to make claims regarding causation, performing func-
tional studies in vitro and animal studies will be needed
in order to unravel precise biological mechanisms. Fi-
nally, to maximize power for discovery, the present co-
horts were chosen to be highly similar in regard to
demographics, type of trauma, and time since trauma
exposure. Thus, the degree to which these findings on
active duty, predominantly European-ancestry military
men, may generalize to females, civilians, or other ances-
tries is unclear.
Conclusions
In summary, this is the largest study on methylation
changes associated with the development of combat-
related PTSD to date. Our observations point towards
the implication of biologically interesting genes such as
HLA region which is involved in immune-related pro-
cesses, HEXDC which also has been suggested to play a
role in immunity, and MAD1L1, a PTSD-related gene
recently identified in the large MVP. These findings
strengthen the notion that specific DNA methylation
profiles are involved in the development of combat-
related PTSD. Larger longitudinal studies and integrative
efforts are now needed to build upon these preliminary
findings in order to understand their functional conse-
quences and integrate them more broadly into our
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current understanding of the (epi)genomic basis of
PTSD.
Methods
Discovery datasets
Marine Resiliency Study
The Marine Resiliency Study (MRS) [49] is a prospective
PTSD study of Marines and Navy personnel deployed to
Iraq or Afghanistan. PTSD symptoms were assessed ap-
proximately 1 month before deployment, and 3 and/or 6
months post-deployment using the CAPS and the PTSD
Checklist (PCL) for DSM-IV. Biological samples includ-
ing whole blood were collected at all time points. Infor-
mation on smoking and alcohol use was collected on a
self-report basis. Combat exposure was assessed approxi-
mately 1 week post-deployment using the Deployment
Risk and Resilience Inventory (DRRI). A subset of 63
PTSD cases and 63 controls was selected for the methy-
lation assays and inclusion in the present study. All sub-
jects were free of a PTSD diagnosis at pre-deployment
and had CAPS scores ≤ 25. After return from a ~ 7-
month deployment period, blood samples from PTSD
cases (following the DSM-IV full or partially stringent
diagnosis [50, 51]) were selected either at the 3- or the
6-month follow-up visit, based on when these subjects
had their highest recorded CAPS scores. Subsequently,
controls were frequency matched to the selected cases
for age, ancestry, and time of post-deployment visit. The
study was approved by the institutional review boards of
the University of California San Diego, VA San Diego
Research Service, and Naval Health Research Center. All
subjects provided informed consent.
Army STARRS
The Army Study to Assess Risk and Resilience in Servi-
cemembers (Army STARRS) is a prospective study
among US Army personnel gathering information on
risk and resilience factors for suicidality and psychopath-
ology [52]. All subjects completed a computerized ver-
sion of the Composite International Diagnostic
Interview screening scales (CIDI-SC) and the PCL6
screener for DSM-IV approximately 6 weeks before de-
ployment to Afghanistan, and the PCL-C at 1, 2, and 6
months post-deployment. PTSD diagnosis was assigned
using multiple imputation methods that relied on PCL
and CIDI-SC data [53], and information on trauma ex-
posure was gathered from self-administered questions
on childhood-, adult-, and military-related events. Infor-
mation on smoking and alcohol use was collected on a
self-report basis. Biological samples including whole
blood were collected approximately 6 weeks before de-
ployment and 1 month post-deployment. A subset of 31
cases and 47 controls were selected for the methylation
assays and inclusion in this analysis. All subjects were
free of a PTSD diagnosis at pre-deployment. PTSD cases
were selected based on their PTSD diagnosis at 6
months post-deployment. Controls were PTSD-free sub-
jects matched on age, deployment stress, and childhood
adversity. The study procedures were approved by the
Institutional Review Boards of all collaborating organiza-
tions. All subjects provided informed consent.
Replication dataset: PRISMO
Replication data was obtained from the Prospective Re-
search In Stress-related Military Operations (PRISMO)
study, a prospective study of Dutch military soldiers de-
ployed to Afghanistan [54, 55]. The severity of current
PTSD symptoms was assessed using the Self-Report In-
ventory for PTSD (SRIP), and blood samples were col-
lected approximately 1 month before and 1 and 6
months after deployment. Traumatic stress exposure
during deployment to Afghanistan was assessed with a
deployment experiences checklist. Information on smok-
ing and alcohol use was collected on a self-report basis.
A subset of 29 cases and 33 controls was selected for the
methylation assays and inclusion in this analysis (see [7]
for selection criteria). The study was approved by the
ethical committee of the University Medical Center Ut-
recht, and was conducted in accordance with the Declar-
ation of Helsinki. All subjects provided informed
consent.
Quality control
In all cohorts, longitudinal whole blood DNA methyla-
tion levels were measured using the Illumina Human-
Methylation450K BeadChip. The Psychiatric Genomics
Consortium (PGC)-EWAS quality control pipeline was
used on all three cohorts [5]. Briefly, samples were ex-
cluded when having a probe detection call rate < 90%
and an average intensity value < 50% of the overall sam-
ple mean or < 2,000 arbitrary units (AU). Individual
probes with detection p values > 0.001 or those based on
less than three beads were set to missing. Remaining
probes were excluded when cross-reactivity occurred be-
tween autosomal and sex chromosomes. CpG sites with
missing data for > 10% of samples within cohorts were
excluded (Additional file 1: Table S5). After filtering, the
β-values reflecting methylation levels of individual cyto-
sine residues were normalized to correct for differences
between type I and type II probes using Beta Mixture
Quantile Normalization (BMIQ) [56]. ComBat [57] was
used to correct for remaining issues such as batch and
plate effects. To account for differences in cell type com-
position between samples, proportions of CD8, CD4,
NK, B cells, monocytes, and granulocytes were estimated
for each individual using their unique DNA methylation
profiles. This was estimated using the estimatecellcounts
function in minfi [58].
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Statistical analysis
The normalized β-values were logit transformed to M
values which were used for linear regression analysis.
Post-deployment DNA methylation was modeled as a
function of post-deployment PTSD status while adjust-
ing for pre-deployment DNA methylation; age; changes
in CD4T, CD8T, NK, B cell, and monocyte cell propor-
tions; and principal components (PCs) for ancestry. For
MRS and Army STARRS, the PCs were derived from
available GWAS and PCs 1–3 were included. For
PRISMO, the method described by Barfield and col-
leagues [59] was used to derive PCs from the EWAS
data and PCs 2–4 (see [5]) were included. HC3 standard
errors were calculated using the sandwich R library [60].
Analyses were performed on each cohort independently,
and the obtained p values were combined using a sample
size weighted meta-analysis. Significance was declared at
p < 1.13 × 10−7 after a stringent Bonferroni correction
for 439,897 probes. Possible confounding effects of
changes in smoking and alcohol use were assessed as a
sensitivity analysis.
DMR analysis was performed on a set of 26,000 pre-
defined gene regions within gene bodies, promoter re-
gions, and CpG islands using the mCSEA version 1.2
package for R [61]. Regions were included when anno-
tated to having at least five CpGs. For each study, EWAS
p values, methylation level values, and a phenotype and
covariate data matrix were supplied as program inputs. p
values were derived using 100,000 permutations. A sam-
ple size weighted meta-analysis of DMRs was performed
based on z-score transformations of permutation p
values. Significances of DMRs (p < 1.92 × 10−6) were de-
rived based on a Bonferroni correction for the 26,000
tests performed. All positions and regions were in refer-
ence to GRCh37/hg19.
We considered replication as significant when the ef-
fect directions matched between the discovery and repli-
cation samples and the p values held up to the
Bonferroni correction for the number of replications
attempted (i.e., 4 for the DMPs, 19 for the DMRs) using
a one-sided test.
Detecting genetic effects and links with gene expression
Associations between baseline levels of methylation of
each significant CpG from the second analysis stage and
nearby SNPs (within 500 kilobases; kb) were assessed in
the MRS dataset using PLINK [62] to detect the poten-
tial influence of genetic effects on DNA methylation. For
a given CpG site, the SNP with the lowest p value was
carried forward as an additional covariate in the regres-
sion models as a sensitivity analysis.
For CpGs annotated to genes, we estimated the corre-
lations between baseline or post-deployment CpG
methylation levels and corresponding blood gene
expression in MRS data. We additionally estimated the
correlations between changes in expression and changes
in methylation for these CpGs. Details of mRNA expres-
sion measurement in MRS can be found elsewhere [63].
Briefly, from 124 MRS Marine participants, blood was
drawn at ~ 1month pre-deployment and mRNA levels
were analyzed through sequencing on a Illumina Hi-Seq
2000.
We used the UCSC genome browser tool (http://gen-
ome.ucsc.edu/) to identify if SNPs associated with our
CpGs influenced expression in other tissue types based
on combined expression eQTL data from 44 tissues
from GTEx v6 [64].
Blood-brain correlations
The Blood Brain DNA Methylation Comparison Tool
(http://epigenetics.iop.kcl.ac.uk/bloodbrain/) was used to
assess correlations between the methylation status of the
top hits of the combined meta-analysis in blood and
brain [11]. Specifically, this tool yields Pearson’s correl-
ation coefficients (r) and associated p values for the asso-
ciation of the methylation status of individual CpG sites
in blood and the prefrontal cortex, entorhinal cortex, su-
perior temporal gyrus, and cerebellum.
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Snijders et al. Clinical Epigenetics           (2020) 12:11 Page 10 of 13
Abbreviations
Army STARRS: Army Study to Assess Risk and Resilience in Servicemembers;
BMIQ: Beta Mixture Quantile Normalization; CAPS: Clinician Administered
PTSD Scale; DMP: Differentially methylated position; DMR: Differentially
methylated region; DRRI: Deployment Risk and Resilience Inventory;
eQTL: Expression quantitative trait locus; EWAS: Epigenome-wide association
study; GWAS: Eenome-wide association studies; HLA: Human leukocyte
antigen; LD: Linkage disequilibrium; MRS: Marine Resiliency Study; PCL: PTSD
Checklist; PGC: Psychiatric Genomics Consortium; PRISMO: Prospective
Research In Stress-related Military Operations; PTSD: Post-traumatic stress
disorder; SNP: Single nucleotide polymorphism; SRIP: Self-Report Inventory
for PTSD
Acknowledgements
Acknowledged are Mark A. Geyer (UCSD), Daniel T. O’Connor (UCSD), and all
MRS investigators, as well as the MRS administrative core and data collection
staff. The authors also thank the Marine and Navy Corpsmen volunteers for
military service and participation in MRS.
Authors’ contributions
AXM, AR, CS, and MBS wrote the manuscript. MPB, AXM, CMN, EP, BPFR, CS,
and CHV were involved in the statistical analyses. MPB, AXM, and AR dealt
with the bioinformatics. DGB, EG, RCK, CMN, VBR, AKS, MBS, MU, RJU, and EV
are the study PIs or co-PIs of the three studies, and CMN is managing the
PGC-PTSD group. DGB, SJ, VBR, and MBS contributed the data. MPB, EG, RCK,
CMN, BPFR, RJU, and EV obtained the necessary funding to conduct the
present study. All authors read and approved the final manuscript.
Authors’ information
The views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the VA, NIH, or the US
government.
Funding
This work was supported by the US Army Medical Research and Materiel
Command as well as the National Institute of Mental Health (NIMH;
R01MH108826; R01MH106595).
Funding for MRS was provided by the Marine Corps, Navy Bureau of
Medicine and Surgery (BUMED), VA Health Research and Development
(HSR&D), Veterans Affairs San Diego Healthcare System, Center of Excellence
for Stress and Mental Health, and NIH R01MH093500. Data collection of
PRISMO was funded by the Dutch Ministry of Defense, and DNA methylation
analyses were funded by the VENI Award fellowship from the Netherlands
Organization for Scientific Research (NWO, grant number 916.11.086). Army
STARRS was sponsored by the Department of the Army and funded under
cooperative agreement number U01MH087981 (2009–2015) with the
National Institutes of Health, National Institute of Mental Health (NIH/NIMH).
Availability of data and materials
Since the present study makes use of military datasets which are typically
not shared publicly due to confidentiality reasons, the datasets used and/or
analyzed during the current study are available from the corresponding
author upon reasonable request only.
Ethics approval and consent to participate
The MRS study was approved by the institutional review boards of the
University of California San Diego, VA San Diego Research Service, and Naval
Health Research Center. For Army STARRS, the study procedures were
approved by the Institutional Review Boards of all collaborating
organizations. The PRISMO study was approved by the ethical committee of
the University Medical Center Utrecht, and was conducted in accordance
with the Declaration of Helsinki. All subjects provided informed consent.
Consent for publication
Not applicable
Competing interests
RCK received support for his epidemiological studies from Sanofi Aventis;
was a consultant for Johnson & Johnson Wellness and Prevention, Sage
Pharmaceuticals, Shire, Takeda; and served on an advisory board for the
Johnson & Johnson Services Inc. Lake Nona Life Project. Kessler is a co-owner
of DataStat, Inc., a market research firm that carries out healthcare research.
MBS has in the past 3 years been a consultant for Actelion, Aptinyx, Bionom-
ics, Dart Neuroscience, Healthcare Management Technologies, Janssen, Neu-
rocrine Biosciences, Oxeia Biopharmaceuticals, Pfizer, and Resilience
Therapeutics. The other authors declare that they have no competing
interests.
Author details
1Department of Psychiatry and Neuropsychology, School for Mental health
and Neuroscience, Maastricht University, Maastricht, Limburg, Netherlands.
2Department of Psychiatry, University of California San Diego, La Jolla, CA,
USA. 3Center of Excellence for Stress and Mental Health, Veterans Affairs San
Diego Healthcare System, San Diego, CA, USA. 4Research Service, Veterans
Affairs San Diego Healthcare System, San Diego, CA, USA. 5Department of
Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
6Psychiatry Service, Veterans Affairs San Diego Healthcare System, San Diego,
CA, USA. 7Department of Psychiatry, UMC Utrecht Brain Center, Utrecht,
Utrecht, Netherlands. 8Brain Research & Innovation Centre, Netherlands
Ministry of Defense, Utrecht, Utrecht, Netherlands. 9Department of Family
Medicine and Public Health, University of California San Diego, La Jolla, CA,
USA. 10Department of Health Care Policy, Harvard Medical School, Boston,
MA, USA. 11College of Medicine and Health, University of Exeter Medical
School, Exeter, UK. 12Million Veteran Program, Veterans Affairs San Diego
Healthcare System, San Diego, CA, USA. 13Department of Psychiatry,
Uniformed Services University, Bethesda, MD, USA. 14Arq, Psychotrauma
Research Expert Group, Diemen, North Holland, Netherlands. 15Department
of Psychiatry, Leiden University Medical Center, Leiden, South Holland,
Netherlands. 16Military Mental Healthcare, Netherlands Ministry of Defense,
Utrecht, Utrecht, Netherlands. 17Department of Psychiatry, New York
University School of Medicine, New York, NY, USA. 18Department of Anatomy
and Neurosciences, Amsterdam UMC (location VUmc), Amsterdam, Holland,
Netherlands. 19Department of Psychiatry, Amsterdam UMC (location VUmc),
Amsterdam, Holland, Netherlands. 20Department of Psychiatry and Behavioral
Sciences, Emory University, Atlanta, GA, USA. 21Department of Gynecology
and Obstetrics, Emory University, Atlanta, GA, USA. 22Genomics Program,
University of South Florida College of Public Health, Tampa, FL, USA.
Received: 24 September 2019 Accepted: 19 December 2019
References
1. Association AP. Diagnostic and statistical manual of mental disorders. 5th
ed. Arlington: American Psychiatric Publishing; 2013.
2. Nievergelt CM, Ashley-Koch AE, Dalvie S, Hauser MA, Morey RA, Smith AK,
et al. Genomic approaches to posttraumatic stress disorder: the psychiatric
genomic consortium initiative. Biol Psychiatry. 2018;83(10):831–9.
3. Daskalakis NP, Rijal CM, King C, Huckins LM, Ressler KJ. Recent genetics and
epigenetics approaches to PTSD. Curr Psychiatry Rep. 2018;20(5):30.
4. Sheerin CM, Lind MJ, Bountress K, Nugent NR, Amstadter AB. The genetics
and epigenetics of ptsd: overview, recent advances, and future directions.
Curr Opin Psychol. 2017;14:5–11.
5. Ratanatharathorn A, Boks MP, Maihofer AX, Aiello AE, Amstadter AB, Ashley-
Koch AE, et al. Epigenome-wide association of PTSD from heterogeneous
cohorts with a common multi-site analysis pipeline. Am J Med Genet B
Neuropsychiatr Genet. 2017;174(6):619–30.
6. Kuan PF, Waszczuk MA, Kotov R, Marsit CJ, Guffanti G, Gonzalez A, et al. An
epigenome-wide DNA methylation study of PTSD and depression in World
Trade Center responders. Transl Psychiatry. 2017;7(6):e1158.
7. Rutten BPF, Vermetten E, Vinkers CH, Ursini G, Daskalakis NP, Pishva E, et al.
Longitudinal analyses of the DNA methylome in deployed military
servicemen identify susceptibility loci for post-traumatic stress disorder. Mol
Psychiatry. 2018;23(5):1145–56.
8. Smith AK, Conneely KN, Kilaru V, Mercer KB, Weiss TE, Bradley B, et al.
Differential immune system DNA methylation and cytokine regulation in
post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet.
2011;156B(6):700–8.
9. Story Jovanova O, Nedeljkovic I, Spieler D, Walker RM, Liu C, Luciano M,
et al. DNA methylation signatures of depressive symptoms in middle-aged
and elderly persons: meta-analysis of multiethnic epigenome-wide studies.
JAMA Psychiatry. 2018;75(9):949–59.
Snijders et al. Clinical Epigenetics           (2020) 12:11 Page 11 of 13
10. Nievergelt CM, Maihofer AX, Mustapic M, Yurgil KA, Schork NJ, Miller MW, et al.
Genomic predictors of combat stress vulnerability and resilience in U.S.
Marines: a genome-wide association study across multiple ancestries implicates
PRTFDC1 as a potential PTSD gene. (1873-3360 (Electronic)). 2015;51:459-71.
11. Hannon E, Lunnon K, Schalkwyk L, Mill J. Interindividual methylomic
variation across blood, cortex, and cerebellum: implications for epigenetic
studies of neurological and neuropsychiatric phenotypes. Epigenetics. 2015;
10(11):1024–32.
12. Yehuda R, Hoge CW, McFarlane AC, Vermetten E, Lanius RA, Nievergelt CM,
et al. Post-traumatic stress disorder. Nat Rev Dis Primers. 2015;1:15057.
13. Gelernter J, Sun N, Polimanti R, Pietrzak R, Levey DF, Bryois J, et al.
Genome-wide association study of post-traumatic stress disorder
reexperiencing symptoms in >165,000 US veterans. Nature
Neuroscience. 2019;22(9):1394–401.
14. Nievergelt CM, Maihofer AX, Klengel T, Atkinson EG, Chen C-Y, Choi KW,
et al. International meta-analysis of PTSD genome-wide association studies
identifies sex- and ancestry-specific genetic risk loci. Nature
Communications. 2019;10(1):4558.
15. Mason JM, Morrison DJ, Basson MA, Licht JD. Sprouty proteins: multifaceted
negative-feedback regulators of receptor tyrosine kinase signaling. Trends
Cell Biol. 2006;16(1):45–54.
16. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell.
2010;141(7):1117–34.
17. Zhang JC, Yao W, Hashimoto K. Brain-derived neurotrophic factor (BDNF)-
TrkB signaling in inflammation-related depression and potential therapeutic
targets. Curr Neuropharmacol. 2016;14(7):721–31.
18. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN.
Altered gene expression of brain-derived neurotrophic factor and receptor
tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen
Psychiatry. 2003;60(8):804–15.
19. Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi Y. Brain-
derived neurotrophic factor and tyrosine kinase B receptor signalling in
post-mortem brain of teenage suicide victims. Int J Neuropsychopharmacol.
2008;11(8):1047–61.
20. Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, et al. The
melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates
apoptosis and invasion. Cancer Res. 2011;71(11):3852–62.
21. He XJ, Bian EB, Ma CC, Wang C, Wang HL, Zhao B. Long non-coding RNA
SPRY4-IT1 promotes the proliferation and invasion of U251 cells through
upregulation of SKA2. Oncol Lett. 2018;15(3):3977–84.
22. Guintivano J, Brown T, Newcomer A, Jones M, Cox O, Maher BS, et al.
Identification and replication of a combined epigenetic and genetic
biomarker predicting suicide and suicidal behaviors. Am J Psychiatry. 2014;
171(12):1287–96.
23. Kaminsky Z, Wilcox HC, Eaton WW, Van Eck K, Kilaru V, Jovanovic T, et al.
Epigenetic and genetic variation at SKA2 predict suicidal behavior and post-
traumatic stress disorder. Transl Psychiatry. 2015;5:e627.
24. Boks MP, Rutten BP, Geuze E, Houtepen LC, Vermetten E, Kaminsky Z, et al.
SKA2 methylation is involved in cortisol stress reactivity and predicts the
development of post-traumatic stress disorder (PTSD) After Military
Deployment. Neuropsychopharmacology. 2016;41(5):1350–6.
25. Sadeh N, Spielberg JM, Logue MW, Wolf EJ, Smith AK, Lusk J, et al. SKA2
methylation is associated with decreased prefrontal cortical thickness and
greater PTSD severity among trauma-exposed veterans. Mol Psychiatry.
2016;21(3):357–63.
26. Zaharieva I, Georgieva L, Nikolov I, Kirov G, Owen MJ, O'Donovan MC, et al.
Association study in the 5q31-32 linkage region for schizophrenia using
pooled DNA genotyping. BMC Psychiatry. 2008;8:11.
27. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and
time. Nat Rev Mol Cell Biol. 2007;8(5):379–93.
28. Bolanos-Garcia VM. Formation of multiprotein assemblies in the nucleus: the
spindle assembly checkpoint. Int Rev Cell Mol Biol. 2014;307:151–74.
29. Trost S, Diekhof EK, Mohr H, Vieker H, Kramer B, Wolf C, et al. Investigating the
impact of a genome-wide supported bipolar risk variant of MAD1L1 on the
human reward system. Neuropsychopharmacology. 2016;41(11):2679–87.
30. Zhao L, Chang H, Zhou DS, Cai J, Fan W, Tang W, et al. Replicated
associations of FADS1, MAD1L1, and a rare variant at 10q26.13 with bipolar
disorder in Chinese population. Transl Psychiatry. 2018;8(1):270.
31. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, et al.
Genome-wide association analysis identifies 13 new risk loci for
schizophrenia. Nat Genet. 2013;45(10):1150–9.
32. Su L, Shen T, Huang G, Long J, Fan J, Ling W, et al. Genetic association of
GWAS-supported MAD1L1 gene polymorphism rs12666575 with
schizophrenia susceptibility in a Chinese population. Neurosci Lett. 2016;
610:98–103.
33. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui
A, et al. Genome-wide association analyses identify 44 risk variants and
refine the genetic architecture of major depression. Nat Genet. 2018;
50(5):668–81.
34. Gelernter J. ea. Genome-wide association study of posttraumatic stress
disorder (PTSD) re-experiencing symptoms in >165,000 US veterans. Nature
Neuroscience. 2019;In press.
35. Le-Niculescu H, Roseberry K, Levey DF, Rogers J, Kosary K, Prabha S, et al.
Towards precision medicine for stress disorders: diagnostic biomarkers and
targeted drugs. Molecular Psychiatry. 2019.
36. Levey DF, Gelernter J, Polimanti R, Zhou H, Cheng Z, Aslan M, et al.
Reproducible risk loci and psychiatric comorbidities in anxiety: results from
~200,000 million veteran program participants. bioRxiv. 2019;540245.
37. Pasztoi M, Sodar B, Misjak P, Paloczi K, Kittel A, Toth K, et al. The recently
identified hexosaminidase D enzyme substantially contributes to the
elevated hexosaminidase activity in rheumatoid arthritis. Immunol Lett.
2013;149(1-2):71–6.
38. Alteen MG, Oehler V, Nemcovicova I, Wilson IB, Vocadlo DJ, Gloster TM.
Mechanism of human nucleocytoplasmic hexosaminidase D. Biochemistry.
2016;55(19):2735–47.
39. Stein MB, Chen C-Y, Ursano RJ, Cai T, Gelernter J, Heeringa SG, et al.
Genome-wide association studies of posttraumatic stress disorder in 2
cohorts of US army soldiers. JAMA Psychiatry. 2016;73(7):695–704.
40. Wang Q, Yang C, Gelernter J, Zhao H. Pervasive pleiotropy between
psychiatric disorders and immune disorders revealed by integrative analysis
of multiple GWAS. Hum Genet. 2015;134(11-12):1195–209.
41. Boscarino JA, Forsberg CW, Goldberg J. A twin study of the association
between ptsd symptoms and rheumatoid arthritis. Psychosom Med. 2010;
72(5):481–6.
42. O’Donovan A, Cohen BE, Seal KH, Bertenthal D, Margaretten M, Nishimi K,
et al. Elevated risk for autoimmune disorders in iraq and afghanistan
veterans with posttraumatic stress disorder. Biological Psychiatry. 2015;77(4):
365–74.
43. Beck S, Trowsdale J. The human major histocompatibility complex:
lessons from the DNA sequence. Annu Rev Genomics Hum Genet.
2000;1(1):117–37.
44. Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ. Functional
requirement for class I MHC in CNS development and plasticity. Science
(New York, NY). 2000;290(5499):2155–9.
45. Sankar A, MacKenzie RN, Foster JA. Loss of class I MHC function alters
behavior and stress reactivity. J Neuroimmunol. 2012;244(1):8–15.
46. Debnath M, Berk M, Leboyer M, Tamouza R. The MHC/HLA gene complex in
major psychiatric disorders: emerging roles and implications. Curr Behav
Neurosci Rep. 2018;5(2):179–88.
47. Wang Z, Caughron B, Young MRI. Posttraumatic stress disorder: an
immunological disorder? Front Psychiatry. 2017;8:222.
48. Katrinli S, Lori A, Kilaru V, Carter S, Powers A, Gillespie CF, et al. Association
of HLA locus alleles with posttraumatic stress disorder. Brain Behav Immun.
2019;81:655–8.
49. Baker DG, Nash WP, Litz BT, Geyer MA, Risbrough VB, Nievergelt CM, et al.
Predictors of risk and resilience for posttraumatic stress disorder among
ground combat Marines: methods of the Marine Resiliency Study. Prev
Chronic Dis. 2012;9:E97.
50. Sher L. Recognizing post-traumatic stress disorder. QJM. 2004;97(1):1–5.
51. Smith AK, Ratanatharathorn A, Maihofer AX, Naviaux RK, Aiello AE, Amstadter
AB, et al. Epigenome-wide meta-analysis of PTSD across 10 military and civilian
cohorts identifies novel methylation loci. bioRxiv. 2019;585109.
52. Ursano RJ, Colpe LJ, Heeringa SG, Kessler RC, Schoenbaum M, Stein MB,
et al. The Army study to assess risk and resilience in servicemembers (Army
STARRS). Psychiatry. 2014;77(2):107–19.
53. Kessler RC, Santiago PN, Colpe LJ, Dempsey CL, First MB, Heeringa SG, et al.
Clinical reappraisal of the Composite International Diagnostic Interview
Screening Scales (CIDI-SC) in the Army Study to Assess Risk and Resilience in
Servicemembers (Army STARRS). Int J Methods Psychiatr Res. 2013;22(4):303–21.
54. Reijnen A, Rademaker AR, Vermetten E, Geuze E. Prevalence of mental
health symptoms in Dutch military personnel returning from deployment to
Afghanistan: a 2-year longitudinal analysis. Eur Psychiatry. 2015;30(2):341–6.
Snijders et al. Clinical Epigenetics           (2020) 12:11 Page 12 of 13
55. Eekhout I, Reijnen A, Vermetten E, Geuze E. Post-traumatic stress symptoms
5 years after military deployment to Afghanistan: an observational cohort
study. Lancet Psychiatry. 2016;3(1):58–64.
56. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero
D, et al. A beta-mixture quantile normalization method for correcting probe
design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics.
2013;29(2):189–96.
57. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray
expression data using empirical Bayes methods. Biostatistics. 2007;8(1):
118–27.
58. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ,
Nelson HH, et al. DNA methylation arrays as surrogate measures of cell
mixture distribution. BMC Bioinformatics. 2012;13:86.
59. Barfield RT, Almli LM, Kilaru V, Smith AK, Mercer KB, Duncan R, et al.
Accounting for population stratification in DNA methylation studies. Genet
Epidemiol. 2014;38(3):231–41.
60. Zeileis A. Econometric Computing with HC and HAC covariance matrix
estimators. J Stat Softw. 2004;11:10.
61. Martorell-Marugan J, Gonzalez-Rumayor V, Carmona-Saez P. mCSEA:
Detecting subtle differentially methylated regions; 2018. p. 293381.
62. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D,
et al. PLINK: a tool set for whole-genome association and population-
based linkage analyses. American journal of human genetics. 2007;81(3):
559–75.
63. Breen MS, Maihofer AX, Glatt SJ, Tylee DS, Chandler SD, Tsuang MT, et al.
Gene networks specific for innate immunity define post-traumatic stress
disorder. Molecular psychiatry. 2015;20(12):1538–45.
64. Consortium GT. The genotype-tissue expression (GTEx) project. Nature
Genet. 2013;45(6):580–5.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Snijders et al. Clinical Epigenetics           (2020) 12:11 Page 13 of 13
